Advancing Ultrasound AI for Abdominal Imaging

As ultrasound becomes the first-line tool for diagnosing abdominal conditions, the demand for consistent, high-quality imaging and interpretation has never been greater. At SmartAlpha, we believe the future of ultrasound is not just faster — it’s smarter.

 

Our vision is to democratize ultrasound by embedding artificial intelligence into the most routine, yet complex, imaging workflows — including those involving abdominal ultrasound.

 

Abdominal AI refers to the use of artificial intelligence to assist in acquiring, interpreting, and standardizing ultrasound exams focused on the abdominal region. This includes imaging of the liver, gallbladder, kidneys, pancreas, spleen, urinary bladder, abdominal aorta and associated vascular structures, as well as bowel loops and peritoneal fluid evaluation. These structures are frequently assessed in clinical settings for a wide range of conditions — from biliary obstruction and renal pathologies to ascites, hepatomegaly, or abnormal echotexture in liver parenchyma.

 

Yet these exams often depend heavily on the operator’s expertise and patient factors like BMI, making consistency a challenge. At SmartAlpha, we’re committed to building and refining AI-driven technologies that enhance every stage of the abdominal ultrasound workflow:

 

  • Probe guidance and view recognition to support consistent capture of key abdominal planes (e.g., longitudinal kidney, transverse gallbladder, subcostal liver views)
  • Real-time quality scoring based on organ visibility and probe orientation
  • Organ boundary identification and auto-contour suggestion
  • Support for biometric measurements such as liver length or kidney size
  • Assistance with detecting parenchymal texture differences (e.g., steatosis indicators)
  • Anatomical structure highlighting to improve image interpretation 

 

By combining real-time feedback with AI-powered visual cues, SmartAlpha’s approach enables clinicians to standardize abdominal ultrasound exams, even in varied clinical environments.

 

Our abdominal ultrasound AI is aiming to assisst real-world applications — where time is limited, patients vary, and every scan matters. Whether it’s a routine gallbladder exam, kidney ultrasound for hydronephrosis, or screening for fatty liver disease, AI allows us to reduce variability, improve scanning efficiency, support early detection, empower more healthcare professionals to perform high-quality scans.

 

And because SmartAlpha’s AI operates fully within the ultrasound system, it aligns with our privacy-first, cloud-free philosophy. No data leaves the device. No internet is required. That’s how we help healthcare systems scale ultrasound — responsibly.

 

While today’s AI enhances visualization and scanning, our future focus includes deeper, diagnostic support — especially for ultrasound-driven fatty liver grading, organ morphology assessment, and risk pattern analysis in abdominal organs.

 

SmartAlpha is committed to expanding ultrasound AI across the entire abdominal domain, creating tools that complement — not replace — clinical expertise. Our work spans both the technological and clinical dimensions of ultrasound, ensuring every advancement supports better care delivery.

 

SmartAlpha brings together experts in artificial intelligence, software engineering, and medical imaging to shape the next generation of ultrasound AI. Our goal is simple:

Make high-quality abdominal ultrasound accessible, consistent, and scalable — everywhere.

From point-of-care clinics to global screening programs, abdominal AI can play a pivotal role in unlocking earlier insights and faster decisions.

 

Regulatory Notice: SmartAlpha’s abdominal AI technologies are currently under development and are not yet cleared or approved for clinical use in any jurisdiction. The features and capabilities described in this article are intended to illustrate SmartAlpha’s research direction and product vision. Any future use of these technologies in clinical practice will be subject to applicable regulatory approvals, including those from authorities such as the FDA, CE Notified Bodies, or other relevant national agencies.